SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

SAN

86.18

+0.87%↑

MRK1

111.9

+1.63%↑

ARGX

801

-0.25%↓

PHIA

23.43

+0.26%↑

ONC.US

347.12

-0.66%↓

Search

Laboratorios Farmaceuticos Rovi SA

Închisă

SectorSănătate

57.95 0.35

Rezumat

Modificarea prețului

24h

Curent

Minim

57.75

Maxim

58

Indicatori cheie

By Trading Economics

Venit

31M

58M

Vânzări

51M

210M

P/E

Medie Sector

24.703

106.172

EPS

1.135

Randament dividend

1.59

Marjă de profit

27.571

Angajați

2,197

EBITDA

4.2M

35M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+55.31% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.59%

2.31%

Statistici piață

By TradingEconomics

Capitalizare de piață

-253M

3B

Deschiderea anterioară

57.6

Închiderea anterioară

57.95

Sentimentul știrilor

By Acuity

50%

50%

147 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 nov. 2025, 10:30 UTC

Câștiguri

How Google Finally Leapfrogged Rivals With New Gemini Rollout -- WSJ

22 nov. 2025, 10:30 UTC

Achiziții, Fuziuni, Preluări

Investors Clamor for a Peek Behind the Private Markets Curtain -- WSJ

22 nov. 2025, 09:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

21 nov. 2025, 22:42 UTC

Market Talk

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21 nov. 2025, 21:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

21 nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 nov. 2025, 21:47 UTC

Market Talk

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21 nov. 2025, 21:43 UTC

Market Talk

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21 nov. 2025, 20:18 UTC

Market Talk

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21 nov. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21 nov. 2025, 19:48 UTC

Market Talk

Precious Metals Fall for the Week -- Market Talk

21 nov. 2025, 19:44 UTC

Câștiguri

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21 nov. 2025, 19:37 UTC

Market Talk

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21 nov. 2025, 19:27 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

21 nov. 2025, 19:27 UTC

Market Talk
Câștiguri

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21 nov. 2025, 19:20 UTC

Market Talk

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21 nov. 2025, 18:44 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21 nov. 2025, 18:37 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21 nov. 2025, 18:34 UTC

Market Talk
Câștiguri

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21 nov. 2025, 18:28 UTC

Câștiguri

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov. 2025, 18:03 UTC

Market Talk

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21 nov. 2025, 17:24 UTC

Market Talk

Global Equities Roundup: Market Talk

21 nov. 2025, 17:24 UTC

Market Talk

Intuit Seen on Path to Increase Growth -- Market Talk

21 nov. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 nov. 2025, 17:05 UTC

Market Talk

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21 nov. 2025, 16:56 UTC

Market Talk

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21 nov. 2025, 16:47 UTC

Market Talk

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21 nov. 2025, 16:35 UTC

Achiziții, Fuziuni, Preluări

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21 nov. 2025, 16:09 UTC

Câștiguri

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov. 2025, 15:59 UTC

Market Talk

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

55.31% sus

Prognoză pe 12 luni

Medie 90 EUR  55.31%

Maxim 90 EUR

Minim 90 EUR

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

147 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat